09.08.2018 • NewsCRBCRB GroupM+W

Former Long-time M+W Executive Gerald Schneider Joins CRB Group

Gerald Schneider joins CRB Group GmbH as managing director.
Gerald Schneider joins CRB Group GmbH as managing director.

Gerald Schneider, a long-time business leader at M+W Group, has joined US competitor CRB Group as managing director for European commercial operations.

Schneider (54), who had been with M+W Group for more than 20 years, served at the Stuttgart, Germany-based company’s Central Europe division as chief financial officer since 2005 and as managing director since 2015. He holds a track record of establishing and developing multiple new offices, successfully restructuring business units and integrating new teams. As CFO, he held responsibility for company commercial affairs and led an international team of 60 employees. 

At CRB Group, a provider of design and consulting solutions for the global life science industry, Schneider’s role will be to provide leadership for CRB’s European offices, working collaboratively with operational leaders and staff. He will hold ultimate responsibility for CRB’s European commercial operations and execute business support systems for legal services, business licensing, project and business contracts, project controls, human resources, finance and accounting.

“We are extremely excited to have Gerald join our team in Europe. Aside from being a great cultural fit with CRB, his broad experience in business operations outside of the United States will be a tremendous asset to our growing international operations,” Ryan Schroeder, CRB’s president, said.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.